Target intelligence / Profile preview

Agglutinin-like protein 3 (Als3p) (Als3p)

Target
Als3p
Molecular classification
Agglutinin-like sequence (ALS) family [1, 14], Cell wall protein [10, 14], Adhesin [1, 6], Invasin [1, 6], GPI-anchored protein [1, 10]
01

Overview

Agglutinin-like protein 3 (Als3p) is a multifunctional cell surface protein of the fungal pathogen Candida albicans, belonging to the Agglutinin-Like Sequence (ALS) family [1, 14]. It is a hypha-specific protein that functions as both an adhesin and an invasin, playing a pivotal role in the organism's virulence and ability to cause disease [1, 6]. Als3p mediates the attachment of C. albicans to host epithelial and endothelial cells, as well as to extracellular matrix proteins and other microorganisms [1, 9]. Furthermore, it acts as an invasin by binding to host cell receptors such as E-cadherin and N-cadherin, which triggers the endocytosis of the fungus into host tissues [1, 4, 6]. Beyond its roles in adhesion and invasion, Als3p is essential for biofilm formation on medical devices and for iron acquisition from host ferritin [1, 12, 15]. Because of its high expression during infection and its critical functions, Als3p is a major target for immunotherapeutic strategies, including the NDV-3A vaccine, which induces protective antibody and T-cell responses to prevent mucosal and systemic candidiasis [2, 3, 8].

Other names
Als3Agglutinin-like sequence 3rAls3p-NHypha-specific surface protein Als3
02

Mechanism of action

Vaccines targeting Als3p induce anti-Als3p antibodies and CD4+ T-cell responses (specifically Th1 and Th17) that block fungal adhesion to host cells, inhibit invasion by preventing binding to cadherins, and enhance opsonophagocytic killing by immune cells such as neutrophils and macrophages [2, 3, 5, 7].

03

Biological functions

Cell adhesion [1, 14]Host cell invasion [1, 6]Biofilm formation [1, 12, 15]Iron acquisition [1, 14]Morphological transition [1, 15]
04

Disease associations

Infection [1, 2]Candidiasis [1, 8]Biofilm-associated infection [7, 15]
05

Safety considerations

Potential for cross-reactivity with other ALS family members [1, 2]Requirement for robust Th1/Th17 immune responses for therapeutic efficacy [2, 3]
06

Interacting drugs

NDV-3 [8]

3 more in the full profile.

07

Biomarkers

Anti-Als3p serum IgG antibody titers [3]

Beyond the preview

Go deeper on Agglutinin-like protein 3 (Als3p) (Als3p).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agglutinin-like protein 3 (Als3p) (Als3p).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call